| BID | 42.01 | ASK | 43.99 | ||
| Open | 43.50 | Previous Close | 41.00 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 43.67 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 0.48 | Finscreener Ranking | — - | |
| Insiders Trans % 3/6/12 mo. | -/-/- | Value Ranking | ★★★+ 55.00 | |
| Insiders Value % 3/6/12 mo. | -/-/- | Growth Ranking | — - | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/- | Income Ranking | — - | |
| Market Cap | 1.25B | Earnings Rating | — | |
| Price Range Ratio 52W % | 45.18 | Earnings Date | 4th Mar 2021 |
Today's Price Range 41.2543.77 | 52W Range 9.6484.49 |
Summary:
Sell
| Technical Indicators: | Sell |
| Moving Averages: | Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | -10.58% | ||
| 1 Month | -23.32% | ||
| 3 Months | 11.44% | ||
| 6 Months | 288.38% | ||
| 1 Year | 251.01% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -22.52 | |||
ROE last 12 Months | -92.79 | |||
ROA (5Y Avg) | -19.99 | |||
ROA last 12 Months | -80.12 | |||
ROC (5Y Avg) | -24.20 | |||
ROC last 12 Months | -86.93 | |||
Return on invested Capital Q | -16.22 | |||
Return on invested Capital Y | -91.98 | |||
Assets Turnover | 0.00 | |||
Receivables Turnover | 2.10 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -24.10 | ||||
| 22.75 | ||||
| 303.50 | ||||
| - | ||||
| -62.90 | ||||
| -1.69 | ||||
| 22.75 | ||||
| 2.21 | ||||
| 1.38B | ||||
| Forward PE | - | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 12.00 | ||||
| 12.30 | ||||
| 0.00 | ||||
| 0.01 | ||||
| -73.90 | ||||
| Leverage Ratio | 1.10 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -1.60 | ||||
| -578.00 | ||||
| -571.70 | ||||
| - | ||||
| - |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 4.33M | ||||
| 0.15 | ||||
| - | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2020 | -0.54 | -0.48 | 11.11 |
| Q03 2020 | -0.58 | -0.50 | 13.79 |
| Q04 2019 | - | -0.08 | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| - | - | - | - |
| Next Report Date | - |
| Estimated EPS Next Report | -0.54 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 1.17M |
| Shares Outstanding | 28.76M |
| Trades Count | 13.59K |
| Dollar Volume | 80.98M |
| Avg. Volume | 1.50M |
| Avg. Weekly Volume | 1.24M |
| Avg. Monthly Volume | 1.32M |
| Avg. Quarterly Volume | 1.51M |
DermTech Inc (NASDAQ: DMTK) stock closed at 43.46 per share at the end of the most recent trading day (a 6% change compared to the prior day closing price) with a volume of 1.17M shares and market capitalization of 1.25B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 64 people. DermTech Inc CEO is John D Dobak.
The one-year performance of DermTech Inc stock is 251.01%, while year-to-date (YTD) performance is 33.97%. DMTK stock has a five-year performance of %. Its 52-week range is between 9.64 and 84.49, which gives DMTK stock a 52-week price range ratio of 45.18%
DermTech Inc currently has a PE ratio of -24.10, a price-to-book (PB) ratio of 22.75, a price-to-sale (PS) ratio of 303.50, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -80.12%, a ROC of -86.93% and a ROE of -92.79%. The company’s profit margin is -%, its EBITDA margin is -571.70%, and its revenue ttm is $4.33 Million , which makes it $0.15 revenue per share.
Of the last four earnings reports from DermTech Inc, there were 2 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.54 for the next earnings report. DermTech Inc’s next earnings report date is -.
The consensus rating of Wall Street analysts for DermTech Inc is Strong Buy (1), with a target price of $43.67, which is +0.48% compared to the current price. The earnings rating for DermTech Inc stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
DermTech Inc has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
DermTech Inc has a Sell technical analysis rating based on Technical Indicators (ADX : 30.90, ATR14 : 7.03, CCI20 : -111.02, Chaikin Money Flow : -0.02, MACD : -3.33, Money Flow Index : 46.53, ROC : -7.55, RSI : 40.66, STOCH (14,3) : 20.16, STOCH RSI : 0.54, UO : 41.45, Williams %R : -79.84), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of DermTech Inc in the last 12-months were:
DermTech Inc
DermTech Inc is an emerging growth molecular diagnostic company. The company is engaged in marketing and developing novel non-invasive genomic tests to aid in the diagnosis of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. While the company generates revenue through laboratory services.
CEO: John D Dobak
Telephone: +1 858 450-4222
Address: 11099 N. Torrey Pines Road, La Jolla 92037, CA, US
Number of employees: 64
